FDA denies approval of generic Lovenox

Novartis AG and biotechnology firm Momenta Pharmaceuticals' generic version of anti-clotting drug Lovenox has been rejected by the FDA due to concerns about the treatment's effect on the immune system. Momenta executives said they would work with the FDA to address their concerns.

View Full Article in:

Boston Globe (tiered subscription model), The · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ